A new class of medicines could give doctors the ability to awaken underperforming genes in patients who currently have no treatment options.
Boston-area startup RaNA Therapeutics is developing a novel kind of medicine that can boost the activity of genes that may be silenced or underactive and thus cause disease. The medicine would use a small RNA-like molecule that blocks the function of a long RNA molecule that is hampering the expression of such a gene.
{iframe}http://www.technologyreview.com/news/517386/rna-drugs-target-genes-that-were-once-off-limits/0{/iframe}